Citius Pharmaceuticals CTXR Stock
Citius Pharmaceuticals Price Chart
Citius Pharmaceuticals CTXR Financial and Trading Overview
| Citius Pharmaceuticals stock price | 0.48 USD |
| Previous Close | 0.52 USD |
| Open | 0.52 USD |
| Bid | 0.38 USD x 200 |
| Ask | 0.69 USD x 200 |
| Day's Range | 0.5 - 0.53 USD |
| 52 Week Range | 0.47 - 2.19 USD |
| Volume | 116.67K USD |
| Avg. Volume | 526.43K USD |
| Market Cap | 14M USD |
| Beta (5Y Monthly) | 1 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.62 USD |
| Forward Dividend & Yield | N/A (0%) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4 USD |
CTXR Valuation Measures
| Enterprise Value | 13.74M USD |
| Trailing P/E | N/A |
| Forward P/E | -0.3542361 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 1.9708892 |
| Price/Book (mrq) | 0.2102638 |
| Enterprise Value/Revenue | 1.934 |
| Enterprise Value/EBITDA | N/A |
Trading Information
Citius Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 1 |
| 52-Week Change | -62.85% |
| S&P500 52-Week Change | 15.77% |
| 52 Week High | 2.19 USD |
| 52 Week Low | 0.47 USD |
| 50-Day Moving Average | 0.6 USD |
| 200-Day Moving Average | 0.7 USD |
CTXR Share Statistics
| Avg. Volume (3 month) | 526.43K USD |
| Avg. Daily Volume (10-Days) | 157.07K USD |
| Shares Outstanding | 27.45M |
| Float | 26.96M |
| Short Ratio | 9.46 |
| % Held by Insiders | 1.79% |
| % Held by Institutions | 4.95% |
| Shares Short | 5.56M |
| Short % of Float | 20.62% |
| Short % of Shares Outstanding | 20.26% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor | 1:25 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | September 30, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | September 30, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -670.22% |
| Gross Margin | 77.34% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -26.56% |
| Return on Equity (ttm) | -81.085% |
Income Statement
| Revenue (ttm) | 7.11M USD |
| Revenue Per Share (ttm) | 0.33 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 5.5M USD |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -46274056 USD |
| Diluted EPS (ttm) | -1.75 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 17.01M USD |
| Total Cash Per Share (mrq) | 0.62 USD |
| Total Debt (mrq) | 7.18M USD |
| Total Debt/Equity (mrq) | 9.46 USD |
| Current Ratio (mrq) | 0.839 |
| Book Value Per Share (mrq) | 2.426 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -34867204 USD |
| Levered Free Cash Flow (ttm) | -36803784 USD |
Profile of Citius Pharmaceuticals
| Country | United States |
| State | NJ |
| City | Cranford |
| Address | 11 Commerce Drive |
| ZIP | 07016 |
| Phone | 908 967 6677 |
| Website | https://citiuspharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 23 |
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Q&A For Citius Pharmaceuticals Stock
What is a current CTXR stock price?
Citius Pharmaceuticals CTXR stock price today per share is 0.48 USD.
How to purchase Citius Pharmaceuticals stock?
You can buy CTXR shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Citius Pharmaceuticals?
The stock symbol or ticker of Citius Pharmaceuticals is CTXR.
Which industry does the Citius Pharmaceuticals company belong to?
The Citius Pharmaceuticals industry is Biotechnology.
How many shares does Citius Pharmaceuticals have in circulation?
The max supply of Citius Pharmaceuticals shares is 27.45M.
What is Citius Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Citius Pharmaceuticals PE Ratio is now.
What was Citius Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Citius Pharmaceuticals EPS is -1.62 USD over the trailing 12 months.
Which sector does the Citius Pharmaceuticals company belong to?
The Citius Pharmaceuticals sector is Healthcare.
Citius Pharmaceuticals CTXR included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
27599.89 USD — |
+0.45
|
7.66B USD — | 27592.56 USD — | 27722.75 USD — | — - | 7.66B USD — |
|
US Tech Capital Market Composite
RCMP
US
|
127.9 USD — |
-1.07
|
— — | 127.87 USD — | 130.12 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1292.45 USD — |
-2.09
|
— — | 1285.97 USD — | 1330.32 USD — | — - | — — |
- {{ link.label }} {{link}}
